Author's Reply: “Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?”
Digestive and Liver Disease · 2024
DOI: 10.1016/j.dld.2023.12.006 ↗Kurz gefasst
Leserbrief in der Zeitschrift Digestive and Liver Disease, 2024. Verfasst von Paula Sousa und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Viseu-Tondela Hospital Centre, Viseu, Portugal. Hauptthemen laut MEDLINE: Immunologic Factors, Crohn Disease. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Viseu-Tondela Hospital Centre, Viseu, Portugal.
- Center for Health Technology and Services Research (CINTESIS), Porto, Portugal; Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal; CINTESIS@RISE,…
Zitieren
APA
Sousa, P., & Magro, F. (2024). Author's Reply: “Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?”. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2023.12.006
Vancouver
Sousa P, Magro F. Author's Reply: “Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?”. Digestive and Liver Disease. 2024. doi:10.1016/j.dld.2023.12.006
BibTeX
@article{Sousa2024,
author = {Sousa, Paula and Magro, Fernando},
title = {Author's Reply: “Immunomodulator combination versus mono therapy: Does combination therapy have an impact on infliximab therapy?”},
journal = {Digestive and Liver Disease},
year = {2024},
doi = {10.1016/j.dld.2023.12.006}
}
EUVIMED